New hope for patients with Treatment-Resistant autoimmune disease
NCT ID NCT07080346
Summary
This study tested whether the medication upadacitinib could help adults with Behcet's syndrome whose symptoms weren't controlled by standard treatments. Twenty-seven patients took the drug daily for 48 weeks alongside their existing medications. Researchers monitored whether symptoms like mouth sores, skin lesions, and eye inflammation improved, and tracked safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHCET SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.